1. Avoiding the needle: A quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery.
- Author
-
Stewart KT, Jafari H, Pattillo J, Santos J, Jao C, Kwok K, Singh N, Lee AYY, Kwon JS, and McGinnis JM
- Subjects
- Humans, Female, Middle Aged, Aged, Anticoagulants administration & dosage, Anticoagulants economics, Anticoagulants adverse effects, Postoperative Complications prevention & control, Interrupted Time Series Analysis, Factor Xa Inhibitors administration & dosage, Factor Xa Inhibitors economics, Factor Xa Inhibitors adverse effects, Factor Xa Inhibitors therapeutic use, Adult, Pyridones administration & dosage, Pyridones adverse effects, Pyridones economics, Pyridones therapeutic use, Genital Neoplasms, Female surgery, Pyrazoles administration & dosage, Pyrazoles economics, Pyrazoles adverse effects, Pyrazoles therapeutic use, Quality Improvement, Gynecologic Surgical Procedures adverse effects, Venous Thromboembolism prevention & control, Venous Thromboembolism etiology, Enoxaparin administration & dosage, Enoxaparin economics, Enoxaparin adverse effects
- Abstract
Objective: Patients undergoing gynecologic cancer surgery at our centre are recommended up to 28 days of enoxaparin for extended post-operative thromboprophylaxis (EP). Baseline survey revealed 92% patient adherence, but highlighted negative effects on patient experience due to the injectable route of administration. We aimed to improve patient experience by reducing pain and bruising by 50%, increasing adherence by 5%, and reducing out-of-pocket cost after introducing apixaban as an oral alternative for EP., Methods: In this interrupted time series quality improvement study, gynecologic cancer patients were offered a choice between apixaban (2.5 mg orally twice daily) or enoxaparin (40 mg subcutaneously once daily) at time of discharge. A multidisciplinary team informed project design, implementation, and evaluation. Process interventions included standardized orders, patient and care team education programs. Telephone survey at 1 and 6 weeks and chart audit informed outcome, process, and balancing measures., Results: From August to October 2022, 127 consecutive patients were included. Apixaban was chosen by 84%. Survey response rate was 74%. Patients who chose apixaban reported significantly reduced pain, bruising, increased confidence with administration, and less negative impact of the medication (p < 0.0001 for all). Adherence was unchanged (92%). The proportion of patients paying less than $125 (apixaban cost threshold) increased from 45% to 91%. There was no difference in bleeding and no VTE events., Conclusions: Introduction of apixaban for EP was associated with significant improvement in patient-reported quality measures and reduced financial toxicity with no effect on adherence or balancing measures. Apixaban is the preferred anticoagulant for EP at our centre., Competing Interests: Declaration of competing interest The authors declare that there are no conflicts of interest. AL reports consulting fees from Bayer, Bristol-Myers Squibb, Janssen and Pfizer unrelated to this project., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF